Home Magazines Editors-in-Chief FAQs Contact Us

Diffuse alveolar hemorrhage: a narrative review

Journal of Lung, Pulmonary & Respiratory Research
Samantha A Lopez  Samantha A Lopez 

PDF Full Text


This review discusses clinical presentation of DAH, diagnosis of the underlying histology’s, treatment options, as well as morbidity and mortality rates. Diffuse alveolar hemorrhage (DAH) is considered a life-threatening pulmonary complication in patients with systemic autoimmune disorders, hematologic malignancies, and coagulation disorders. DAH is distinguished by acute onset of hypoxia and alveolar infiltrates that may lead to progressive alveolar bleeding. Early diagnosis and recognition are crucial for survival. Treatment for DAH involves treating both the underlying condition and the autoimmune damage of


diffuse alveolar hemorrhage, corticosteroids, hemoptysis, hypoxia, diffuse lung infiltrates, systemic auto immune diseases, hematopoietic stem cell transplant